{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:30:56Z","timestamp":1782307856371,"version":"3.54.5"},"reference-count":178,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Monoclonal antibodies (mAbs) are an important medical innovation in modern medicine. They are an effective therapy for several subtypes of leukaemia but may have undesirable effects, which may be minimised through the provision of interdisciplinary care including a pharmacist. The goals of this narrative review were twofold: first, to summarise the literature on the side effects of mAbs and the challenges of their preparation, and to provide recommendations for the safe preparation of mAb drug formulations for clinicians. Second, to suggest clinical roles for pharmacists to improve patient safety and clinical outcomes for leukaemia patients receiving mAb therapy. The review covers data from 178 scientific and official sources of information on the types of targeted immunobiological drugs for the treatment of various types of leukaemia. The results are a detailed description of the possible side effects from mAb therapy and a list of suggested actions that can be taken to prevent them. Pharmaceutical aspects of the use of mAbs, such as pharmacoeconomics, compounding and stability, are also discussed. The discussion is organised according to the current classification of leukaemia. The drugs considered include blinatumomab, inotuzumab ozogamicin, gemtuzumab ozogamicin, rituximab, ofatumumab, obinutuzumab, and alemtuzumab. The review offers a comprehensive resource to equip pharmacists and other clinicians to optimise mAb therapy and promote the safe use of these novel therapies.<\/jats:p>","DOI":"10.3390\/pharmacy13060169","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:59:46Z","timestamp":1763715586000},"page":"169","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5418-1684","authenticated-orcid":false,"given":"Anastasiia","family":"Ryzhuk","sequence":"first","affiliation":[{"name":"Pharmaceutical Chemistry Department, National University of Pharmacy, 61002 Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2222-8180","authenticated-orcid":false,"given":"Sergiy M.","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry and Molecular Materials, V. N. Karazin Kharkiv National University, 61022 Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Georgiyants","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care and Pediatric Anesthesiology, Kharkiv National Medical University, 61022 Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Vysotska","sequence":"additional","affiliation":[{"name":"Department of Propaedeutics of Internal Medicine and Physical Rehabilitation, V. N. Karazin Kharkiv National University, 61022 Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8794-8010","authenticated-orcid":false,"given":"Victoriya","family":"Georgiyants","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, National University of Pharmacy, 61002 Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ali, S.R., Nigam, M., and Mishra, A.P. (2025). Monoclonal Antibodies and Cancer. Biotechnology and Cancer Therapeutics, Springer.","DOI":"10.1007\/978-981-96-4959-4"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Justiz-Vaillant, A., Pandit, B.R., Unakal, C., Vuma, S., and Akpaka, P.E. (2025). A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy. Antibodies, 14.","DOI":"10.3390\/antib14020035"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kumar, M., Jalota, A., Sahu, S.K., and Haque, S. (2024). Therapeutic Antibodies for the Prevention and Treatment of Cancer. J. Biomed. Sci., 31.","DOI":"10.1186\/s12929-024-00996-w"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Delgado, M., and Garcia-Sanz, J.A. (2023). Therapeutic Monoclonal Antibodies against Cancer: Present and Future. Cells, 12.","DOI":"10.3390\/cells12242837"},{"key":"ref_5","unstructured":"World Health Organization (2024). Clinical Research Landscape of Monoclonal Antibodies: Report on 2014\u20132023 Period, WHO."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"110115","DOI":"10.1016\/j.isci.2024.110115","article-title":"Monoclonal Antibody Biosimilars for Cancer Treatment","volume":"27","author":"Broer","year":"2024","journal-title":"iScience"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Malhotra, S., Cameron, A.I., Gotham, D., Burrone, E., Gardner, P.J., Loynachan, C., Morin, S., Scott, C.P., and P\u00e9rez-Casas, C. (2024). Novel Approaches to Enable Equitable Access to Monoclonal Antibodies in Low- and Middle-Income Countries. PLOS Glob. Public Health, 4.","DOI":"10.1371\/journal.pgph.0003418"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40290-023-00473-z","article-title":"Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond","volume":"37","author":"Gieber","year":"2023","journal-title":"Pharm. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Huang, J., Chan, S.C., Ngai, C.H., Lok, V., Zhang, L., Lucero-Prisno, D.E., Xu, W., Zheng, Z.J., Elcarte, E., and Withers, M. (2022). Disease Burden, Risk Factors, and Trends of Leukaemia: A Global Analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.904292"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1612702","DOI":"10.1155\/2022\/1612702","article-title":"The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030","volume":"2022","author":"Du","year":"2022","journal-title":"J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lu, R.M., Hwang, Y.C., Liu, I.J., Lee, C.C., Tsai, H.S., Li, H.-J., and Wu, H.-C. (2020). Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci., 27.","DOI":"10.1186\/s12929-019-0592-z"},{"key":"ref_13","unstructured":"International Agency for Research on Cancer (2025, October 14). Cancer Today: GLOBOCAN 2020. Global Cancer Observatory 2022. Available online: https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/maps-heatmap?mode=population&cancers=36."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lin, Q., Mao, L., Shao, L., Li, Z., Qingmei, H., Honghu, Z., Jie, J., and Liangshun, Y. (2020). Global, regional, and national burden of chronic myeloid leukemia, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.580759"},{"key":"ref_15","unstructured":"International Agency for Research on Cancer (2025, October 14). Cancer Today: GLOBOCAN\u2014Maps-heatmap (Cancers = 36, Types = 1). Global Cancer Observatory 2022. Available online: https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/maps-heatmap?mode=population&cancers=36&types=1."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.sapharm.2024.02.006","article-title":"Impact of Pharmacist-Led Interventions on Medication-Related Problems among Patients Treated for Cancer: A Systematic Review and Meta-Analysis of Randomized Control Trials","volume":"20","author":"Fentie","year":"2024","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.3390\/curroncol31080312","article-title":"Clinical Pharmacist-Led Interventions for Improving Breast Cancer Management\u2014A Scoping Review","volume":"31","author":"Staynova","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.annemergmed.2019.07.015","article-title":"Adverse events of novel therapies for hematologic malignancies: What emergency physicians should know","volume":"75","author":"Shah","year":"2020","journal-title":"Ann. Emerg. Med."},{"key":"ref_19","first-page":"2020-7-2","article-title":"Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukaemia","volume":"9","author":"Dalia","year":"2020","journal-title":"Drugs Context"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.54097\/6rjc1w05","article-title":"Problems Facing Monoclonal Antibody Technology","volume":"102","author":"Zhang","year":"2024","journal-title":"Highlights Sci. Eng. Technol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cai, J., Li, M.X., Lu, S., Shen, D., Xie, W., Zhu, J.-J., Jiang, G.-J., and Lu, C.-X. (2025). Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-89145-3"},{"key":"ref_22","first-page":"124877","article-title":"Novel strategies in systemic and local administration of therapeutic monoclonal antibodies","volume":"667 Pt A","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_23","unstructured":"Amgen, Inc. (2024, June 14). Blincyto\u00ae (Blinatumomab) for Injection, Prescribing Information. U.S. Food and Drug Administration 2024, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125557Orig1s028Correctedlbl.pdf."},{"key":"ref_24","unstructured":"Pfizer, Inc. (2025, October 05). Besponsa\u2122 (Inotuzumab Ozogamicin) for Injection, Prescribing Information. U.S. Food and Drug Administration 2017, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf."},{"key":"ref_25","unstructured":"Pfizer, Inc. (2025, October 05). Mylotarg\u2122 (Gemtuzumab Ozogamicin) for Injection, Prescribing Information. U.S. Food and Drug Administration 2020, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf."},{"key":"ref_26","unstructured":"Novartis Pharmaceuticals Corporation (2025, October 05). ARZERRA\u00ae (Ofatumumab) Injection, Prescribing Information. U.S. Food and Drug Administration 2016, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125326s062lbl.pdf."},{"key":"ref_27","unstructured":"Genentech, Inc. (2025, October 05). Gazyva\u00ae (Obinutuzumab) Injection, Prescribing Information. U.S. Food and Drug Administration 2020, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125486s037s038lbl.pdf."},{"key":"ref_28","unstructured":"Genzyme Corporation (2025, October 05). Campath\u00ae (Alemtuzumab) Injection, Prescribing Information. U.S. Food and Drug Administration 2023, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103948s5171lbl.pdf."},{"key":"ref_29","unstructured":"Genentech, Inc., and Biogen, Inc. (2025, October 05). Rituxan\u00ae (Rituximab) Injection, Prescribing Information. U.S. Food and Drug Administration 2012, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","article-title":"Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukaemia: Past progress, current research and future directions","volume":"17","author":"Short","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","unstructured":"Chennamadhavuni, A., Iyengar, V., Mukkamalla, S.K.R., and Shimanovsky, A. (2023). Leukaemia, StatPearls."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3343\/alm.2024.0194","article-title":"Reclassification of Acute Myeloid Leukemia According to the 2022 World Health Organization Classification and the International Consensus Classification Using Open-Source Data","volume":"45","author":"Yun","year":"2025","journal-title":"Ann. Lab. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Saleem, S., Amin, J., Sharif, M., Mallah, G.A., Kadry, S., and Gandomi, A.H. (2022). Leukaemia segmentation and classification: A comprehensive survey. Comput. Biol. Med., 150.","DOI":"10.1016\/j.compbiomed.2022.106028"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3233\/HAB-211511","article-title":"Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review","volume":"30","author":"Pourmontaseri","year":"2022","journal-title":"Hum. Antibodies"},{"key":"ref_36","first-page":"419","article-title":"Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia","volume":"15","author":"Abuasab","year":"2021","journal-title":"Biologics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","article-title":"Monoclonal antibodies in acute lymphoblastic leukemia","volume":"125","author":"Jabbour","year":"2015","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Molica, M., Perrone, S., Andriola, C., and Rossi, M. (2023). Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukaemia: A Work in Progress. Cancers, 15.","DOI":"10.3390\/cancers15205060"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","article-title":"Targeting acute myeloid leukemia through antibody engineering: Innovations in immunotherapy and combination regimens","volume":"25","author":"Noormohamadi","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Isidori, A., Cerchione, C., Daver, N., DiNardo, C., Garcia-Manero, G., Konopleva, M., Jabbour, E., Ravandi, F., Kadia, T., and de la Fuente Burguera, A. (2021). Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.656218"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/PPO.0000000000000577","article-title":"Monoclonal Antibodies in Acute Myeloid Leukemia\u2014Are We There Yet?","volume":"28","author":"Fathi","year":"2022","journal-title":"Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41375-025-02579-6","article-title":"Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients","volume":"39","author":"Welch","year":"2025","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sergi, C.M. (2023). Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing. Advancements in Cancer Research, Exon Publications. Chapter 6.","DOI":"10.36255\/advancements-in-cancer-research"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Perutelli, F., Jones, R., Griggio, V., Vitale, C., and Coscia, M. (2022). Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.837531"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000416","article-title":"Targeted Therapy in Chronic Lymphocytic Leukemia","volume":"25","author":"Kipps","year":"2019","journal-title":"Cancer J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12703\/r\/10-35","article-title":"Recent advances in understanding chronic myeloid leukemia: Where do we stand?","volume":"10","author":"Kumar","year":"2021","journal-title":"Fac. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/B978-0-12-816920-9.00009-2","article-title":"Clinical features of tumours (Chapter 9)","volume":"Volume 2","author":"Bignold","year":"2020","journal-title":"Principles of Tumours"},{"key":"ref_50","unstructured":"Puckett, Y., and Chan, O. (2025). Acute Lymphocytic Leukaemia."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.trecan.2023.06.004","article-title":"Transcription factor abnormalities in B-ALL leukemogenesis and treatment","volume":"9","author":"Yin","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Aureli, A., Marziani, B., Venditti, A., Sconocchia, T., and Sconocchia, G. (2023). Acute Lymphoblastic Leukaemia Immunotherapy Treatment: Now, Next, and Beyond. Cancers, 15.","DOI":"10.20944\/preprints202305.0620.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","article-title":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: Results from the NEUF study","volume":"13","author":"Boissel","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101246","DOI":"10.1016\/j.htct.2023.06.006","article-title":"All about blinatumomab: The bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia","volume":"46","author":"Mirfakhraie","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_55","first-page":"2783","article-title":"Measurable residual disease in acute lymphoblastic leukaemia: Methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12254-025-01034-7","article-title":"Blinatumomab is changing the standard of care paradigms of newly diagnosed and relapsed pediatric B-cell acute lymphoblastic leukemia","volume":"18","author":"Attarbaschi","year":"2025","journal-title":"Memo"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: Post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pourhassan, H., Agrawal, V., Pullarkat, V., and Aldoss, I. (2023). Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1237031"},{"key":"ref_61","first-page":"1352","article-title":"Clinical study of blinatumomab in the treatment of adult relapsed\/refractory Ph-negative acute B-lymphoblastic leukemia","volume":"31","author":"Ouyang","year":"2023","journal-title":"PubMed"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/OP.21.00843","article-title":"Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukaemia: An Urgent Plea for New Treatments Is Being Answered!","volume":"18","author":"DuVall","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JOP.19.00197","article-title":"Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukaemia in Adolescents and Young Adults","volume":"16","author":"Wang","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Marrapodi, M.M., Mascolo, A., di Mauro, G., Mondillo, G., Pota, E., and Rossi, F. (2022). The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.929122"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: Management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gao, W., Yu, J., Sun, Y., Song, Z., Liu, X., Han, X., Li, L., Qiu, L., Zhou, S., and Qian, Z. (2025). Adverse events in the nervous system associated with blinatumomab: A real-world study. BMC Med., 23.","DOI":"10.1186\/s12916-025-03913-6"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/ejh.13569","article-title":"Blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"106","author":"Queudeville","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_68","first-page":"e21583","article-title":"Cytokine Release Syndrome Following Blinatumomab Therapy","volume":"14","author":"Ojemolon","year":"2022","journal-title":"Cureus"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e18518","DOI":"10.1200\/JCO.2025.43.16_suppl.e18518","article-title":"Cytokine release syndrome among acute lymphocytic leukemia adults undergoing treatment with blinatumomab in the United States","volume":"43","author":"Tannous","year":"2025","journal-title":"JCO"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","article-title":"No free rides: Management of toxicities of novel immunotherapies in ALL, including financial","volume":"2","author":"Jain","year":"2018","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s10238-023-01000-9","article-title":"Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia","volume":"23","author":"Quattrone","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e2018029","DOI":"10.4084\/mjhid.2018.029","article-title":"Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab","volume":"10","author":"So","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_74","unstructured":"Amgen (2025, May 01). Blincyto (Blinatumomab) Injection, for Intravenous Use [Prescribing Information], Available online: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125557s030lbl.pdf."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s41669-023-00411-4","article-title":"Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France","volume":"7","author":"Caillon","year":"2023","journal-title":"PharmacoEconomics Open"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.jval.2024.03.588","article-title":"EE289 Cost-Effectiveness Analysis of Blinatumomab for Advanced Acute Lymphoblastic Leukemia in Japan","volume":"27","author":"Ozeki","year":"2024","journal-title":"Value Health"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107560","DOI":"10.1016\/j.leukres.2024.107560","article-title":"Cost-effectiveness of blinatumomab for the treatment of B-precursor acute lymphoblastic leukemia pediatric patients with high-risk first-relapse in Mexico","volume":"145","author":"Camacho","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1182\/blood-2024-194076","article-title":"Mathematical Optimization of Blinatumomab Preparation Method Simplifies Dosing and Administration","volume":"144","author":"Mizuguchi","year":"2024","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2146\/ajhp150420","article-title":"Minimizing waste during preparation of blinatumomab infusions","volume":"73","author":"Marini","year":"2016","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1177\/1078155220966394","article-title":"Pediatric blinatumomab preparation: Risk assessment on SmPC for software compliance","volume":"27","author":"Cirino","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1182\/blood-2022-157117","article-title":"Safety and Pharmacokinetics of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results from a Phase 1b Study","volume":"140","author":"Zugmaier","year":"2022","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/aob-25-5","article-title":"Immunotherapy with blinatumomab in B-cell acute lymphoblastic leukemia: A narrative review of efficacy, toxicity, and patient management in relapse and consolidation","volume":"10","author":"Zugmaier","year":"2025","journal-title":"Ann. Blood"},{"key":"ref_83","first-page":"121","article-title":"Financial Impact and Utilization of a Pharmacist-Driven Home Infusion Pathway for Blinatumomab in Patients Requiring Short-Term Inpatient Monitoring after Outpatient Initiation of Blinatumomab","volume":"15","author":"Seago","year":"2025","journal-title":"J. Hematol. Oncol. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1182\/blood-2021-148865","article-title":"Successful Outpatient Administration of Blinatumomab Infusion in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"138","author":"Pinkney","year":"2021","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Takano, M., Inoue, M., Ikeda, Y., Kage, H., Inokawa, T., Nakadate, K., Yasu, T., Tsuda, Y., and Goto, K. (2023). SEM Observation of the Filter after Administration of Blinatumomab: A Possibility of Leakage during Home Administration Using a Portable Infusion Pump. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065729"},{"key":"ref_86","unstructured":"Pfizer (2025, August 01). Besponsa (Inotuzumab Ozogamicin) for Injection, for Intravenous Use [Prescribing Information]. Available online: https:\/\/www.pfizermedical.com\/besponsa."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","article-title":"Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies","volume":"67","author":"Shor","year":"2015","journal-title":"Mol Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood.2020008544","article-title":"Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL","volume":"137","author":"Kirchhoff","year":"2021","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2024023930","article-title":"Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"key":"ref_90","unstructured":"Pfizer Inc. (2025, August 01). Besponsa (Inotuzumab Ozogamicin) for Injection, for Intravenous Use [Prescribing Information]. Available online: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=13312."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/j.clml.2017.07.027","article-title":"Management of Important Adverse Events Associated with Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"17","author":"Kebriaei","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"35820","DOI":"10.1002\/cncr.35820","article-title":"INO-CD22: A Multicenter, Real-World Study of Inotuzumab Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"131","author":"Papayannidis","year":"2025","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab Ozogamicin versus Standard of Care in Relapsed or Refractory Acute Lymphoblastic Leukemia: Final Report and Long-Term Survival Follow-Up from the Randomized, Phase III INO-VATE Study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Wells, K.N., and Martino, J.G. (2023). Evaluation of the inpatient use of inotuzumab ozogamicin and creation of appropriate use guidelines. J. Oncol. Pharm. Pract.","DOI":"10.1177\/10781552231188974"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-0041-1731860","article-title":"Inotuzumab Ozogamicin Monotherapy as an Outpatient Salvage Treatment in Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia: Compassionate Access","volume":"42","author":"Radhakrishnan","year":"2021","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40273-019-00779-4","article-title":"The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal","volume":"37","author":"Cox","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40273-019-00812-6","article-title":"Cost Effectiveness of Blinatumomab versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States","volume":"37","author":"Delea","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jval.2018.09.225","article-title":"PCN142\u2014Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria","volume":"21","author":"Djambazov","year":"2018","journal-title":"Value Health"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s41669-021-00287-2","article-title":"Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden","volume":"6","author":"Jakobsson","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10198-020-01207-7","article-title":"Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan\u2019s health care system","volume":"21","author":"Lee","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e230142","DOI":"10.57264\/cer-2023-0142","article-title":"Real-world Use of Inotuzumab Ozogamicin Is Associated with Lower Health Care Costs Than Blinatumomab in Patients with Acute Lymphoblastic Leukemia in the First Relapsed\/Refractory Setting","volume":"13","author":"Murphy","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and Acute Myeloid Leukaemia: Real World Data on Decision to Treat and Outcomes From the Swedish Acute Leukaemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De Novo Acute Myeloid Leukaemia: A Population-Based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results (SEER) Database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"103607","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukaemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1097\/CM9.0000000000003195","article-title":"Leukocyte immunoglobulin-like receptor B4 (LILRB4) in acute myeloid leukaemia: From prognostic biomarker to immunotherapeutic target","volume":"22","author":"Li","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1021\/acsomega.8b03627","article-title":"Structural Characterization of the Aggregates of Gemtuzumab Ozogamicin","volume":"4","author":"Jiang","year":"2019","journal-title":"ACS Omega"},{"key":"ref_109","unstructured":"Pfizer Inc. (2024, March 23). MYLOTARG (Gemtuzumab Ozogamicin) for Injection, for Intravenous Use [Prescribing Information]. Available online: https:\/\/www.pfizermedical.com\/patient\/mylotarg."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukaemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukaemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"20406207231154708","DOI":"10.1177\/20406207231154708","article-title":"Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukaemia","volume":"14","author":"Swaminathan","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","article-title":"Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukaemia","volume":"13","author":"Cortes","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","first-page":"100525","article-title":"Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 Regimen in Fit Newly Diagnosed Acute Myeloid Leukemia (AML) Patients","volume":"24","author":"Dargenio","year":"2025","journal-title":"Leukemia Res. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/bloodadvances.2024014570","article-title":"Gastrointestinal Toxicity of Gemtuzumab Ozogamicin: Real-Life Data from the AMLCG, SAL, and CELL Study Groups","volume":"9","author":"Knabe","year":"2025","journal-title":"Blood Adv."},{"key":"ref_117","unstructured":"EMA (2025, August 21). MYLOTARG (Gemtuzumab Ozogamicin)\u2014European Medicines Agency. Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mylotarg-epar-product-information_en.pdf."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s41669-021-00278-3","article-title":"Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK","volume":"5","author":"Brockbank","year":"2021","journal-title":"PharmacoEconomics Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40273-020-00976-6","article-title":"Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia","volume":"39","author":"Mamolo","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/CEOR.S302097","article-title":"Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with CD33-Positive Acute Myeloid Leukaemia in Spain","volume":"13","author":"Mareque","year":"2021","journal-title":"Clinicoecon. Outcomes Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Cairoli, R., Furneri, G., Di Virgilio, R., Veggia, B., and Ferrara, F. (2023). Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy. BMC Health Serv. Res., 23.","DOI":"10.1186\/s12913-023-09054-x"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukaemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","article-title":"Anti-CD20 monoclonal antibodies: Reviewing a revolution","volume":"14","author":"Casan","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3960\/jslrt.20036","article-title":"Pathogenesis of chronic lymphocytic leukaemia and the development of novel therapeutic strategies","volume":"60","author":"Kikushige","year":"2020","journal-title":"J. Clin. Exp. Hematopathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12325-011-0032-2","article-title":"Rituximab in chronic lymphocytic leukaemia","volume":"28","author":"James","year":"2011","journal-title":"Adv. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: Serious adverse events associated with the use of rituximab\u2014A critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/rheumatology\/ken168","article-title":"Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs","volume":"47","author":"Ostensen","year":"2008","journal-title":"Rheumatology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy: Results of a multicentre, randomised, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s12032-011-9974-0","article-title":"The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy","volume":"29","author":"Chen","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/cc4907","article-title":"Clinical review: Specific aspects of acute renal failure in cancer patients","volume":"10","author":"Darmon","year":"2006","journal-title":"Crit Care"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ihj.2015.10.374","article-title":"Updated cardiac concerns with rituximab use: A growing challenge","volume":"68","author":"Verma","year":"2016","journal-title":"Indian Heart J."},{"key":"ref_133","first-page":"6372","article-title":"Managing a cardiac side effect of rituximab","volume":"9","author":"Patil","year":"2020","journal-title":"Indian J. Drugs Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","article-title":"Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an application observation","volume":"153","author":"Gellrich","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D34NS1K655","article-title":"A review of rituximab in cutaneous medicine","volume":"12","author":"Scheinfeld","year":"2006","journal-title":"Dermatol. Online J."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Urru, S.A.M., Spila Alegiani, S., Guella, A., Traversa, G., and Campomori, A. (2021). Safety of switching between rituximab biosimilars in onco-hematology. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-85563-1"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14712598.2019.1665017","article-title":"Rituximab biosimilars for lymphoma in Europe","volume":"19","author":"Jurczak","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/HS9.0000000000000515","article-title":"Introduction of Biosimilar Rituximab: A Hospital Perspective","volume":"5","author":"Cheesman","year":"2020","journal-title":"Hemasphere"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/jppr.1827","article-title":"Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: A systematic meta-analysis review","volume":"52","author":"Song","year":"2022","journal-title":"J. Pharm. Pract. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40259-019-00376-z","article-title":"Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin\u2019s Lymphoma: A Systematic Review and Meta-analysis","volume":"33","author":"Lee","year":"2019","journal-title":"BioDrugs"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vhri.2023.01.011","article-title":"Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R","volume":"36","author":"Santos","year":"2023","journal-title":"Value Health Reg. Issues"},{"key":"ref_144","first-page":"2284240318784289","article-title":"Budget Impact Analysis of Rituximab Biosimilar in Italy from the Hospital and Payer Perspectives","volume":"5","author":"Rognoni","year":"2018","journal-title":"Glob. Reg. Health Technol. Assess."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s12325-017-0522-y","article-title":"The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries","volume":"34","author":"Brodszky","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1358\/dot.2010.46.7.1497416","article-title":"Ofatumumab in the treatment of chronic lymphocytic leukaemia","volume":"46","author":"Tsimberidou","year":"2010","journal-title":"Drugs Today"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/OTT.S72845","article-title":"New developments in the management of chronic lymphocytic leukaemia: Role of ofatumumab","volume":"9","author":"Laurenti","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_148","first-page":"6","article-title":"Arzerra (ofatumumab) receives FDA approval for patients with previously untreated chronic lymphocytic leukaemia for use in combination with chlorambucil","volume":"4","author":"Raedler","year":"2014","journal-title":"Oncol. Pract. Manag."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12962-017-0071-x","article-title":"Estimating outcomes and cost effectiveness using a single-arm clinical trial: Ofatumumab for double-refractory chronic lymphocytic leukemia","volume":"15","author":"Hatswell","year":"2017","journal-title":"Cost Eff. Resour. Alloc."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.clinthera.2016.02.005","article-title":"Cost-effectiveness of first-line chronic lymphocytic leukemia treatments when full-dose fludarabine is unsuitable","volume":"38","author":"Soini","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14737167.2021.1913056","article-title":"Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: A systematic review","volume":"21","author":"Chen","year":"2021","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Lakhotia, R., Melani, G., Pittaluga, S., Gordon, M.J., Phelan, J.D., Muppidi, J.R., Tadese, A., Evans, S., Jaffe, E.S., and Staudt, L.M. (2025). The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas. Br. J. Haematol., ahead of print.","DOI":"10.1111\/bjh.20219"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2217\/FON.15.179","article-title":"Obinutuzumab in chronic lymphocytic leukaemia","volume":"11","author":"Dupuis","year":"2015","journal-title":"Future Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/DDDT.S104869","article-title":"Obinutuzumab in chronic lymphocytic leukaemia: Design, development and place in therapy","volume":"11","author":"Fischer","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_157","first-page":"370","article-title":"Obinutuzumab: A novel anti-CD20 monoclonal antibody for chronic lymphocytic leukaemia","volume":"6","author":"Evans","year":"2015","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Bourrier, N., Landego, I., Bucher, O., Squires, M., Streu, E., Hibbert, I., Whiteside, T., Gibson, S.B., Geirnaert, M., and Johnston, J.B. (2022). Real world risk of infusion reactions and efficacy of front-line obinutuzumab plus chlorambucil compared with other front-line treatments for chronic lymphocytic leukaemia. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09256-2"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.bneo.2025.100075","article-title":"Short-duration infusion of obinutuzumab with venetoclax in chronic lymphocytic leukaemia: A prospective observational study","volume":"2","author":"Pullarkat","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Wang, C., Dong, Y., Men, P., Zhang, R., Xiao, Y., Bu, Y., Qin, Y., Zhang, X., Dou, Q., and Yang, Y. (2025). Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: A rapid review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1426772"},{"key":"ref_161","first-page":"615","article-title":"Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma","volume":"27","author":"Spencer","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jval.2022.11.002","article-title":"Cost-effectiveness of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for the first-line treatment of adult patients with chronic lymphocytic leukemia: An extended societal view","volume":"26","author":"Do","year":"2023","journal-title":"Value Health"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/jcp.47.4.313","article-title":"Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin\u2019s lymphomas","volume":"47","author":"Salisbury","year":"1994","journal-title":"J. Clin. Pathol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2567.1998.00615.x","article-title":"Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-cell lymphoma cell lines, and subsequent emergence of CD52-deficient cells","volume":"95","author":"Rowan","year":"1998","journal-title":"Immunology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.seminhematol.2008.02.001","article-title":"Antibody therapy for chronic lymphocytic leukaemia","volume":"45","author":"Christian","year":"2008","journal-title":"Semin. Hematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.V104.11.478.478","article-title":"Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG)","volume":"104","author":"Stilgenbauer","year":"2004","journal-title":"Blood"},{"key":"ref_168","unstructured":"Eden, R.E., and Coviello, J.M. (2025). Chronic Myelogenous Leukaemia."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.beha.2006.05.001","article-title":"Monoclonal antibodies and immunoconjugates in acute myeloid leukaemia","volume":"19","author":"Amadori","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-065X.2010.00963.x","article-title":"Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors","volume":"238","author":"Kondo","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/15476910801897409","article-title":"Hazard Identification and Risk Assessment for Biologics Targeting the Immune System","volume":"5","author":"Weir","year":"2008","journal-title":"Immunotoxicology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.clinthera.2023.10.016","article-title":"Clinically approved monoclonal antibodies-based immunotherapy: Association with glycemic control and impact role of clinical pharmacist for cancer patient care","volume":"46","author":"Sheta","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_173","first-page":"446","article-title":"Compounding with biotechnology products, Part 2: Product-specific considerations","volume":"26","author":"Allen","year":"2022","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.farma.2024.12.001","article-title":"Stability of thermolabile drugs at room temperature: A review","volume":"49","author":"Li","year":"2025","journal-title":"Farm. Hosp."},{"key":"ref_175","unstructured":"Stabilis (2025, October 02). Blinatumomab\u2014Stability in Solutions. Stabilis Database. Available online: https:\/\/stabilis.org\/Monographie.php?IdMolecule=960&codeLangue=EN-en."},{"key":"ref_176","unstructured":"Stabilis (2025, October 05). Rituximab\u2014Stability in solutions. Stabilis Database. Available online: https:\/\/stabilis.org\/Monographie.php?IdMolecule=280."},{"key":"ref_177","unstructured":"Stabilis (2025, October 05). Obinutuzumab\u2014Stability in Solutions. Stabilis Database. Available online: https:\/\/stabilis.org\/Monographie.php?IdMolecule=977."},{"key":"ref_178","unstructured":"Stabilis (2025, September 25). Alemtuzumab\u2014Stability in Solutions. Stabilis Database. Available online: https:\/\/stabilis.org\/Monographie.php?IdMolecule=558."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/169\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:35:12Z","timestamp":1763717712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/13\/6\/169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":178,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pharmacy13060169"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy13060169","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}